A free alternative to Citeline and Evaluate
Every drug in development for any disease, target or company: who owns it, how far it has got and what happens next. Free to start, $49 a month for everything. No sales call.
- A source on every row
- Updated every day
- No payment card
Obesity
95 of 101 checked · data updated 18 Nov 2026
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Trials |
|---|---|---|---|---|---|
GIP + GLP-1 |
Eli Lilly · Public LLY |
Approved | Nov 2026soonPhase 3 trial completes | 19 trials | |
Amylin + GLP-1 |
Novo Nordisk · Public NVO |
Filed | Dec 2026US FDA decision expected in Q4 2026 (company guidance, exact date not public) | 4 trials | |
GIP + GLP-1 + glucagon |
Eli Lilly · Public LLY |
Phase 3 | Nov 2026soonPhase 3 trial completes | 6 trials | |
— |
Phase 3 | 31 Dec 2026Phase 3 trial completes | 1 trial | ||
NLRP3 inhibitor unconfirmed |
BioAge Labs · Public BIOA |
Phase 2 | 30 Nov 2026soonPhase 2 trial completes | 1 trial |
OpenLandscape vs Citeline, Evaluate and Cortellis
Every drug in development and its trials, without the annual contract or the sales call. For sales forecasts and deal values, the big databases are still the right tool.
| OpenLandscape | Citeline, Evaluate, Cortellis | |
|---|---|---|
| Price | $0 to start, $49 a month | Price on request |
| Free plan | Yes | — |
| Contract | Monthly, cancel any time | Annual contract |
| Getting started | Sign up with your email, today | A sales call first |
| Every drug in development, by disease, target or company | Yes | Yes |
| Trials, readouts and FDA and EMA decisions | Yes | Yes |
| Where the data comes from | Public registries, a link on every row | Public sources plus their own research |
| Open source | Yes | — |
| Sales forecasts, deal values and analyst notes | — | Yes |
An alternative to Pharmaprojects, Trialtrove, Biomedtracker and Cortellis
What each is for, and what you get in OpenLandscape instead.
- PharmaprojectsCiteline · Drug pipelinesCovered
Every drug in active trials for a disease, target or company, with its owner and stage.
- TrialtroveCiteline · Clinical trialsCovered
The trials behind each drug, from ClinicalTrials.gov and the EU register.
- BiomedtrackerCiteline · Catalysts and approval oddsPartly
The next readouts and FDA and EMA dates on every list, and an email when they change. No approval odds.
- CortellisClarivate · Pipelines, deals and regulatoryPartly
Pipelines, trials and regulator decisions in one place. No deal values.
Questions about switching from Citeline
Is there a free alternative to Citeline?
Yes. OpenLandscape lists every drug in development for a disease, target or company, read from public registries every day, with a source on every row. Free shows the top 10 of any list and one landscape in full, with no payment card. Solo is $49 a month for every list in full, downloads and alerts.
How much do Citeline and Evaluate Pharma cost?
Neither shows a price: both are sold on annual contracts, with the price on request. OpenLandscape is free to start and $49 a month before VAT, and you can cancel any time.
Is OpenLandscape as complete as Citeline?
For drugs in clinical trials, it reads the public registries and regulators every day. It does not have sales forecasts, deal values, analyst notes, or preclinical drugs that are not yet in a registry. 207 drugs are checked by hand; the rest are grouped automatically from registry names and marked "not checked yet".
Where does the data come from?
ClinicalTrials.gov, the EU Clinical Trials register, FDA, EMA and SEC filings, and company press releases where a registry has not caught up. Every row links to the record it came from.
Can I export to Excel?
Yes, on Solo. Every list downloads as a CSV file that opens in Excel.
Can I use it from ChatGPT or Claude?
Yes. Add the OpenLandscape connector and ask about any drug, company or trial; answers come with their sources. Free includes 25 questions a month.
Who uses it?
Business development and competitive intelligence people at small and mid-size biotechs, consultants who build landscapes for clients, and investors. If you need forecasts or deal values, the big databases are still the right tool.
Build your competitive landscape, free
Search any disease, drug, target or company. One landscape in full is free, for good.